» Authors » James L Stevens

James L Stevens

Explore the profile of James L Stevens including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 691
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wijaya L, Kunnen S, Trairatphisan P, Fisher C, Crosby M, Schaefer K, et al.
Cell Biol Toxicol . 2025 Feb; 41(1):49. PMID: 39982567
Nephrotoxicity caused by drug or chemical exposure involves complex mechanisms as well as a temporal integration of injury and repair responses in different nephron segments. Distinct cellular transcriptional programs regulate...
2.
Berridge B, Bucher J, Sistare F, Stevens J, Chappell G, Clemons M, et al.
Toxicol Sci . 2023 Dec; 198(1):4-13. PMID: 38134427
Throughput needs, costs of time and resources, and concerns about the use of animals in hazard and safety assessment studies are fueling a growing interest in adopting new approach methodologies...
3.
Wijaya L, Gabor A, Pot I, van de Have L, Saez-Rodriguez J, Stevens J, et al.
Toxicol Sci . 2023 Nov; 198(1):14-30. PMID: 38015832
Drug-induced liver injury (DILI) remains the main reason for drug development attritions largely due to poor mechanistic understanding. Toxicogenomic to interrogate the mechanism of DILI has been broadly performed. Gene...
4.
Russomanno G, Sison-Young R, Livoti L, Coghlan H, Jenkins R, Kunnen S, et al.
Toxicol Sci . 2023 Aug; 196(1):112-125. PMID: 37647630
To minimize the occurrence of unexpected toxicities in early phase preclinical studies of new drugs, it is vital to understand fundamental similarities and differences between preclinical species and humans. Species...
5.
Callegaro G, Schimming J, Pinero Gonzalez J, Kunnen S, Wijaya L, Trairatphisan P, et al.
iScience . 2023 Mar; 26(3):106094. PMID: 36895646
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human models can address the species translation but might not replicate...
6.
Callegaro G, Kunnen S, Trairatphisan P, Grosdidier S, Niemeijer M, den Hollander W, et al.
Arch Toxicol . 2021 Oct; 95(12):3745-3775. PMID: 34626214
Mechanism-based risk assessment is urged to advance and fully permeate into current safety assessment practices, possibly at early phases of drug safety testing. Toxicogenomics is a promising source of mechanisms-revealing...
7.
Wijaya L, Trairatphisan P, Gabor A, Niemeijer M, Keet J, Alcala Morera A, et al.
Biochem Pharmacol . 2021 May; 190:114591. PMID: 33957093
Drug-induced liver injury (DILI) is the most prevalent adversity encountered in drug development and clinical settings leading to urgent needs to understand the underlying mechanisms. In this study, we have...
8.
Corton J, Hill T, Sutherland J, Stevens J, Rooney J
Toxicol Sci . 2020 Jul; 177(1):11-26. PMID: 32603430
Chemical-induced liver cancer occurs in rodents through well-characterized adverse outcome pathways. We hypothesized that measurement of the 6 most common molecular initiating events (MIEs) in liver cancer adverse outcome pathways...
9.
Campos G, Schmidt-Heck W, De Smedt J, Widera A, Ghallab A, Putter L, et al.
Arch Toxicol . 2020 Jan; 94(1):205-217. PMID: 31919559
Inflammation has been recognized as essential for restorative regeneration. Here, we analyzed the sequential processes during onset of liver injury and subsequent regeneration based on time-resolved transcriptional regulatory networks (TRNs)...
10.
Sutherland J, Stevens J, Johnson K, Elango N, Webster Y, Mills B, et al.
Toxicol Sci . 2019 Apr; 170(2):296-309. PMID: 31020328
Applying toxicogenomics to improving the safety profile of drug candidates and crop protection molecules is most useful when it identifies relevant biological and mechanistic information that highlights risks and informs...